Navigation Links
Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
Date:5/8/2008

CRANBURY, N.J., May 8 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) will announce its third quarter, fiscal year 2008 financial results for the period ended March 31, 2008 before the open of the U.S. financial markets on May 13, 2008.

The Company will also conduct a teleconference and live audio webcast hosted by Palatin's executive management team on May 13, 2008 at which they will discuss the results of operations in greater detail and provide an update on corporate developments.

Conference Call / Webcast

-- Q3-Fiscal Year 2008

Conference Call - Live 5/13/2008 at 11:00 a.m. ET

Domestic Dial-In Number 1-888-221-3884

International Dial-In Number 1-913-312-1433

-- Q3-Fiscal Year 2008

Conference Call - Replay 5/13-5/20/2008

Domestic Dial-In Number 1-888-203-1112

International Dial-In Number 1-719-457-0820

Replay Passcode: 1346503

-- Webcast Live and Replay Access http://www.palatin.com

The webcast and replay can be accessed by logging on to the "Investor

Center-Webcasts" section of Palatin's website at

http://www.palatin.com.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. The Company's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. The Company currently has collaborations with AstraZeneca and the Mallinckrodt division of Covidien. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Research and Markets has announced the addition ... to their offering. ... The report provides separate comprehensive analytics for the US, ... of World. Annual estimates and forecasts are provided for the period ... these markets. Market data and analytics are derived from primary and ...
(Date:2/17/2017)... Feb. 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... its oral peptide drug candidates, PTG-100 and PTG-200, ... European Crohn,s and Colitis Organization (ECCO).  The ECCO ... Spain from February 15 – 18, ... data on Protagonist drug candidates PTG-100 and PTG-200. ...
(Date:2/16/2017)... WEST PALM BEACH, Fla. , Feb. 16, ... molecular diagnostics company revolutionizing the development of liquid ... that it has entered into an exclusive license ... who will distribute MDNA,s proprietary liquid biopsy test ... in South Korea . This ...
(Date:2/16/2017)... 2017 Patient Care services ... telemedicine application, new and leading edge therapies and ... boom worldwide. The healthcare sector as whole continues ... and new therapies for companies such as Reliq ... Biosciences, Inc. (NASDAQ: CLRB ), Cytori ...
Breaking Biology Technology:
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
Breaking Biology News(10 mins):